Table 3 Basic characteristics of Romiplostim, Eltrombopag, and Avatrombopag case reports
Characteristic | Romiplostim(n = 2,851) | Eltrombopag(n = 10,297) | Avatrombopag(n = 973) |
|---|---|---|---|
SEX | Â | Â | Â |
 Female | 1235(43.32) | 5256(51.04) | 513(52.72) |
 Male | 1001(35.11) | 4259(41.36) | 385(39.57) |
 NA | 615(21.57) | 782(7.59) | 75(7.71) |
AEs Reports number | 7,311 | 24,561 | 2,332 |
Reporter role | Â | Â | Â |
 Physician | 1277(44.79) | 2948(28.63) | 248(25.49) |
 Other health-professional | 586(20.55) | 595(5.78) | 58(5.96) |
 Consumer | 443(15.54) | 5782(56.15) | 384(39.47) |
 Pharmacist | 538(18.87) | 539(5.23) | 21(2.16) |
 NA | 7(0.25) | 433(4.21) | 262(26.93) |
Reporter_country | Â | Â | Â |
 United States | 1756(61.59) | 5781(56.14) | 917(94.24) |
 Japan | 245(8.59) | 472(4.58) | 0(0) |
 Europe | 178(6.24) | 135(1.31) | 2(0.21) |
 Others | 670(23.50) | 1148(11.15) | 51(5.24) |
 NA | 2(0.07) | 2761(26.81) | 3(0.31) |
Yearsgroup | Â | Â | Â |
 < 18 | 22(0.77) | 6(0.04) | 2(0.21) |
 18–65 | 53(1.86) | 82(0.49) | 17(1.74) |
 ≥ 65 | 45(1.58) | 118(0.71) | 25(2.57) |
 NA | 2731(95.79) | 10,091(98.76) | 929(95.48) |
Reported year | Â | Â | Â |
 2018–2023 | 2851 | 10,297 | 973 |